Brokerages Set Sanofi (NASDAQ:SNY) Price Target at $57.50

Sanofi (NASDAQ:SNY) has received a consensus rating of “Moderate Buy” from the four ratings firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $57.50.

Several equities analysts have recently commented on the company. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th.

Sanofi Price Performance

Shares of SNY stock opened at $48.49 on Thursday. The firm has a fifty day moving average of $52.80 and a two-hundred day moving average of $52.13. The firm has a market cap of $123.06 billion, a P/E ratio of 24.74, a P/E/G ratio of 1.23 and a beta of 0.61. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same period last year, the firm earned $2.55 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, research analysts anticipate that Sanofi will post 4.29 earnings per share for the current fiscal year.

Institutional Trading of Sanofi

Several large investors have recently added to or reduced their stakes in SNY. Barrow Hanley Mewhinney & Strauss LLC raised its position in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after buying an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC lifted its position in Sanofi by 1,153.1% in the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after purchasing an additional 2,306,286 shares during the period. Jennison Associates LLC boosted its stake in Sanofi by 938.0% during the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after purchasing an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after purchasing an additional 1,424,289 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after buying an additional 1,370,232 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.